Clinical trials: Allogeneic Hematopoietic Cell Transplant
Acute GVH Disease
MTX and Steroid as First-line Therapy for aGVHD
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation…
- Trial name
- NCT04960644
- Testing
- MTX, Corticosteroid
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Peking University People's Hospital
Hematologic Malignancies, Nonmalignant Diseases
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609814
- Testing
- Clofarabine, Fludarabine Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
Myelodysplastic Syndromes
CyFluATG in Lower Risk MDS
To evaluate the efficacy of the conditioning regimen with cyclophosphamide, fludarabine, and antithymocyte globulin (CyFluATG) for allogeneic hematopoietic cell transplantation (HCT) in patients with lower risk myelodysplastic…
- Trial name
- NCT06098326
- Testing
- cyclophosphamide, fludarabine, and antithymocyte globulin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Acute Myeloid Leukemia
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with Acute myeloid leukemia (AML)/secondary AML…
- Trial name
- NCT04623216
- Testing
- Sabatolimab, Azacitidine
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Stem Cell Transplantation
Physical Functions in Allogeneic-HSCT Candidates
Physical inactivity and impairments in physical functions have been observed in patients due to hematological malignancy itself and treatments of chemotherapy, radiotherapy, corticosteroids.
- Trial name
- NCT03915249
- Volunteers
- 49 people
- Sponsor
- Gazi University
Leukemia, Myeloid, Acute
A Long-term Follow-up Study of Patients Who Received VOR33
VOR33 long-term follow-up (LTFU) study
- Trial name
- NCT05309733
- Testing
- VOR33
- Where
- 11 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- Vor Biopharma
Hematologic Diseases, Neoplasms
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant…
- Trial name
- NCT05827835
- Testing
- CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Myelodysplastic Syndrome
Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients
Allogeneic blood stem cell transplant remains the only potential curative treatment for myelodysplastic syndromes (MDS) to date.
- Trial name
- NCT01333449
- Testing
- Decitabine
- Where
- Singapore
- Volunteers
- 6 people
- Sponsor
- Singapore General Hospital
T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse
- Trial name
- NCT06686108
- Testing
- Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Transplantation, Hematopoietic Stem Cell
Monitoring of Measles-specific Immune Status in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients
Measles, a highly contagious disease, is potentially serious in adult allogenic hematopoietic stem cell transplant (allo-HSCT) recipients.
- Trial name
- MaRROwVacc (NCT05947864)
- Testing
- Biological samples (blood and oral fluid)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies, Graft-Versus-Host Disease
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3/CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation…
- Trial name
- NCT02342613
- Testing
- Activated PTCy-MILs
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
GATA2, Immunodeficiency
Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency
Background: People with GATA-binding factor 2 (GATA2) deficiency have a mutation on the GATA2 gene. This gene affects immune function.
- Trial name
- NCT05907746
- Testing
- Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes, Acute Leukemia
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia
RATIONALE: Giving chemotherapy and total marrow and lymphoid irradiation before allogeneic hematopoietic cell transplant helps stop the growth of leukemia cells.
- Trial name
- NCT03408210
- Testing
- total body irradiation, total marrow and lymphoid irradiation
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Neutropenic Enterocolitis, Myeloablative Chemotherapy Induced Bone Marrow Aplasia
Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis
Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent…
- Trial name
- NCT02145923
- Testing
- Peripheral blood stem cell mobilisation and collection, High-dose chemotherapy, Bone marrow derived allogeneic MMSCs infusion
- Where
- Russia
- Volunteers
- 16 people
- Sponsor
- Burnasyan Federal Medical Biophysical Center
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause.
- Conditions
- Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
- Trial name
- NCT03922724
- Testing
- ATL-RIC, mRIC, allo HCT
- Where
- 2 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.
- Conditions
- Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases
- Trial name
- NCT00619879
- Testing
- Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Hematological Diseases
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
- Trial name
- AlloCare (NCT06281496)
- Testing
- AlloCare
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.